Itovebi
Payments companies reported to CMS as associated with Itovebi. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Itovebi, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Itovebi
These are the largest totals companies reported as associated with Itovebi. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Komal Jhaveri | New York, NY | Medical Oncology | $8,457.61 |
| Mary Cianfrocca | Duarte, CA | Hematology & Oncology | $6,338.40 |
| William Gradishar | Chicago, IL | Medical Oncology | $5,832.46 |
| Mariana Chavez Macgregor | Houston, TX | Internal Medicine | $5,198.40 |
| Andrew Seidman | New York, NY | Medical Oncology | $3,919.40 |
| Matthew Goetz | Rochester, MN | Medical Oncology | $3,800.00 |
| Yuan Yuan | Pasadena, CA | Medical Oncology | $3,280.00 |
| Min Lu | Stanford, CA | Medical Oncology | $3,059.95 |
| Hope Rugo | San Francisco, CA | Hematology (Internal Medicine) | $2,917.88 |
| Antoinette Tan | Charlotte, NC | Medical Oncology | $2,880.82 |
Prescribed Itovebi?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.